Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

Investigational New Drugs

Volumn 21, Issue 3, 2003, Pages 367-372

  Liu, Glenn ^a   Oettel, Kurt ^a   Bailey, Howard ^a   Van Ummersen, Lynn ^a   Tutsch, Kendra ^a   Staab, Mary Jane ^a   Horvath, Dorothea ^a   Alberti, Dona ^a   Arzoomanian, Rhoda ^a   Rezazadeh, Hamied ^b   McGovern, James ^c   Robinson, Emily ^d   DeMets, David ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b North Central Oncology   (United States)

^c Green Bay Oncology   (United States)

^d Mercy Regional Cancer Center   (United States)

Author keywords

Monoterpenes; Perillyl alcohol; Phase II trial; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; IBUPROFEN; KETOCONAZOLE; MITOXANTRONE; PERILLYL ALCOHOL; SURAMIN; TERPENE DERIVATIVE;

ABDOMINAL CRAMP; ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSTASIS; DRUG ADMINISTRATION ROUTE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; ERUCTATION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOKALEMIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; VOMITING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONOTERPENES; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 10744233371     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025437115182     Document Type: Article

References (16)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 52(1): 23-47, 2002
2. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11(8): 1566-1572, 1993
3. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14: 1756-1764, 1996
4. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-2513, 1999
5. Crowell PL, Gould MN: Chemoprevention of mammary cancer by monoterpenoids. Crit Rev Oncogen 5: 1-22, 1994
6. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN: Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266: 17679-17685, 1991
7. Moul JW, Fridrichs PA, Lance RS, Theune SM, Chang EH: Infrequent ras oncogene mutations in human prostate cancer. Prostate 20: 327-338, 1992
8. Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Londy J, Hand P, Thor A, Sclom J: Expression of ras oncogene p21 in prostate cancer. N Eng J Med 314: 133-137, 1986
9. Voeller HJ, Wilding G, Gelmann EP: V-ras H expression confers hormone-independent in-vitro growth to LNCaP prostate carcinoma cells. Mol Endocrinol 5: 209-216, 1991
10. Jirtle RL, Haag JD, Ariazi EA, Gould MN: Increased levels of M6P-IGF-II receptor and TGF 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53: 3849-3852, 1993
11. Wilding G, Knabbe C, Zugmeier G, Gelmann EP: Differential effects of TGF on human prostate cancer cells in vitro. Mol Cell Endocrinol 62: 79-87, 1989
12. 1 arrest in mammary cells. Proc Annu Meet Am Assoc Cancer Res 38: 263, 1997
13. Ripple GH, Gould M, Stewart J, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey H: Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4: 1159-1164, 1998
14. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM: Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6: 3071-3080, 2000
15. Ripple GH, Gould M, Arzoomanian R, Alberti D, Feierabend C, Simon K, Binger K, Tutsch K, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey H: Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 60: 390-396, 2000
16. Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S: A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol 85: 464-468, 2002